The First Commercial Hire After Series A: W2 Rep, Fractional VP, or Contract Field Force?

A new VP of Commercial joins a Series A health-tech and looks at the pipeline. The founder has been running sales since the seed round. Eight or twelve design partner contracts, all relationship-sourced. A board slide that says "scale provider acquisition" with a number nobody has stress-tested. Ninety days to make the commercial motion run without the founder in every meeting.

Then the question: What do you hire first?

The right answer is not generalizable. It depends on the company's wedge, the buyer they are selling to, and how much of the founder's pipeline was relationship-driven versus product-driven. But across the Series A health-tech founders and commercial leaders I have worked with over the past three years, the same three options surface in almost every planning conversation: a full-time W2 sales rep, a fractional VP of Sales, or a contract field force placed through a marketplace or staffing platform. Each one solves a different problem and creates a different one.

What follows is a working framework, not a recommendation. I have observed all three approaches succeed and fail at companies that looked superficially similar.

What you are actually buying with each option

Before the cost comparison, it helps to be specific about what each model gives you and what it does not.

The trap I see most often is treating these as interchangeable points on a price curve. They are not. A fractional VP cannot make field calls on a hospital system's surgical chief. A W2 rep cannot start meetings next month. A contract rep is unlikely to build your sales playbook from scratch.

The runway math, honestly stated

Series A burn discipline is the single most important constraint shaping this decision. The numbers below use round figures because precise costs vary by city and benefits accounting, but the relative magnitudes hold up.

The headline numbers can look similar. The shape of the spend is what differs. The W2 hire concentrates the bet on one person. The contract field force spreads it across three or four reps in different territories or specialties, which means you are running parallel experiments rather than serial ones.

For a Series A health-tech with a 12-month runway and a Series B target eighteen months out, the parallel-experiment structure has appeal because it generates more pipeline data points faster. That data is what the next investor deck has to defend.

When each option is actually the right call

The generic answer ("it depends") is unhelpful, so let me try to be more useful.

The W2 case is mostly about relationship continuity. A hospital VP relationship that takes fourteen months to convert cannot be rotated through different contract reps. Someone has to carry it from first cold meeting through clinical champion identification through procurement review through legal redlines through signature. That someone has to be permanent, equity-aligned, and emotionally invested in seeing the deal close. There is also a scaling case: if you already know which buyer persona converts and you are pushing a proven pitch into a new territory, a W2 with the right specialty background is the cleaner play than a contract rep who treats your company as one of three accounts. (I have written about the contract vs full-time tradeoffs more directly elsewhere, if that decision is the one you are stuck on.)

Fractional sales leaders sit somewhere else entirely. They are not a substitute for either of the others. They are useful when the playbook has not been written, when the CEO needs a thinking partner before committing to headcount, or when the comp design needs an experienced hand. The pattern I have seen work is roughly three to six months of fractional engagement at the front end of a Series A, while the playbook is being built. The mistake is keeping them on past that. They stop adding marginal value once the motion is documented and the only question left is who is making the calls.

Contract field forces are different in both intent and timing. They are what you reach for when you are still testing. Multiple territories, multiple specialty verticals, sometimes both at once. The core structural advantage is that you can run three or four bets in parallel for roughly what one W2 hire costs, and you get pipeline data back in weeks instead of months. The cost of being wrong is also lower: a W2 you regret is a termination, sometimes a severance, almost always a hit to morale on the rest of the team. A contract rep you regret is a conversation. Different category of mistake. (For a longer treatment of the contract field model and its limits, see the medical sales outsourcing guide.)

I will say one thing that probably belongs in the introduction but fits better here. The model is less determinative than the execution. I have watched companies pick the wrong model and survive through good execution, and watched companies pick the right model and execute poorly. The model sets the ceiling on how fast you can fail. At Series A that ceiling is the thing worth designing around.

The hybrid pattern that works more often than people expect

Across the dozen or so Series A health-techs I have observed in detail, the most common successful pattern is not picking one option. It is sequencing them.

The reason this pattern works is that it isolates risk. The fractional leader carries the playbook risk. The contract reps carry the territory risk. The W2 conversion happens only after both have been answered. Compare that to the alternative, which is hiring one W2 rep for $200K, putting them in one territory, and finding out at month seven whether the territory was the right choice.

The accountability question

The most common pushback I hear from VPs of Commercial considering contract field reps is some version of "how do I know they are actually working." That is a real concern, not a manufactured one.

Contract reps in the medical sales space are typically reporting weekly on activity (meetings booked, meetings completed, opportunities created), monthly on pipeline movement, and quarterly on contracts closed or referrals generated. The cadence is faster than a W2 rep at most companies because the contract structure makes performance review easier. There is no PIP process. If the rep is not generating activity, the contract ends.

The oversight burden is real. A VP of Commercial running three contract reps across three metros is doing more management work than a VP managing one W2 rep. The tradeoff is that the management work is producing data faster.

What I would push back on

A few things I hear in these planning conversations that deserve more skepticism than they get.

The most common is some version of "we will hire a W2 rep and have them start in eight weeks." In healthcare sales, this happens roughly 15% of the time in my observation. The rest of the time the search runs four to six months, and the company has either burned the runway with no field activity or scrambled for an interim solution at month three. (Sara has a piece on this exact failure pattern that goes into the math more deeply.) The eight-week timeline assumes you find a candidate immediately, they have no notice period, no spousal coordination on a move, no competing offer to negotiate. None of those are reliable assumptions for senior healthcare sales talent. The cleaner mental model is to assume four months minimum from kickoff to start date and plan accordingly.

The second is using a large CSO. For Series A health-techs, the major contract sales organizations (IQVIA, Syneos, Amplity) are usually a poor structural fit. Their minimum engagements run ten reps on twelve-month contracts. The math is around $2M and up, which works for a pharma launch but does not work for a $14M Series A trying to deploy capital across product, GTM, and a Series B runway. The CSOs are not wrong to price that way, they are scaled to serve a different buyer. They are just rarely the right answer for a company at this stage.

I also see VPs reach for Upwork or a generalist freelancer platform when budget is tight. I have not seen this work at the senior rep level in healthcare. The talent pool on those platforms is mostly lead-list builders and outbound SDR support, which is a useful capability but not the relationship-building motion that converts at specialty practices and health systems. If you need the latter, you need to look at platforms that vet for healthcare-specific seniority. Mixing the two up wastes a quarter.

A working decision sequence

Compressed into a sequence a VP of Commercial could run in their first thirty days, it looks something like this.

1. Inventory the founder's existing pipeline. How much of it is relationship-driven versus product-driven? If 70%-plus is relationship-driven, you have a transition problem before you have a hiring problem.
2. Pick the buyer you are testing. Hospital service-line director, specialty practice administrator, payer medical director, integrated delivery network supply chain. The hire type follows the buyer, not the reverse.
3. Decide how many territories or verticals you are testing in the next six months. One? You can afford to bet on a W2. Three or more? Contract reps are structurally faster. (The runway math on a single empty or unfilled territory is also worth understanding directly: the cost of an empty medical sales territory is rarely zero.)
4. Decide how much of the playbook exists. If you have a written sales motion, an onboarding doc, and a CRM with structured stages, you can absorb a W2 hire in eight weeks. If you do not, you need a fractional leader to build it before adding bodies.

That last point is the one I see ignored most often. A W2 hire dropped into a company without a playbook spends four months building one and is then judged on pipeline they did not have time to generate. The fractional-first sequence avoids that failure mode.

FAQ